
Psychedelics
Latest News
Latest Videos

Shorts
Podcasts
CME Content
More News

Marijuana’s move to Schedule III has reignited a long-standing contradiction.

Cannabinoids may offer modest, condition-specific analgesic benefits as adjunctive therapy in select chronic pain populations, but current evidence supports a limited role due to inconsistent efficacy, heterogeneity in studies, and safety and pharmacologic concerns.

Vertanical's investigational cannabis-derived therapy VER-01 received FDA breakthrough therapy designation after positive phase 3 data demonstrated significant pain reduction and improved tolerability in patients with chronic low back pain.

A single dose of psilocybin produced rapid and clinically meaningful reductions in depressive symptoms in patients with major depressive disorder.

Emerging evidence supports the use of psilocybin in palliative care, yet Schedule I status uniquely limits access outside of clinical trials in the US.

Psilocybin-assisted psychotherapy significantly increased cocaine abstinence rates and reduced relapse risk in patients with cocaine use disorder.

The actions will support the development of psychedelic-based therapies for PTSD, depressive disorders, and substance use disorders.

The reclassification of medical marijuana to Schedule III marks a major policy shift that expands research and introduces new potential health care challenges.

A federal directive to expedite FDA review and expand research pathways for psychedelic therapies signals a potential shift in mental health treatment.

Canada’s experience demonstrates the risks of sidelining pharmacy in medical cannabis policy.

Pharmacists must adapt to the evolving landscape of psychedelic therapies, focusing on education, patient support, and understanding regulatory challenges.

As psychedelic medicines near approval, pharmacists will become essential guides in safety and education.


Hallucinatory affects associated with psychedelic drugs and Lewy body diseases may have some commonalities.

Engagement and recognition of pharmacist expertise grows as state psychedelic bills expand.

MM120 shows promise in treating generalized anxiety disorder, demonstrating significant symptom relief and a potential shift in psychiatric treatment approaches.

The action follows 2 FDA-issued complete response letters.


























































































































